Page 1921 - Williams Hematology ( PDFDrive )

1896 Part XII: Hemostasis and Thrombosis Chapter 112: Platelet Morphology, Biochemistry, and Function 1897

666. Osterud B: The role of platelets in decrypting monocyte tissue factor. Semin Hematol 700. Plow EF, Collen D: The presence and release of α2-antiplasmin from human platelets.
38(4 Suppl 12):2–5, 2001. Blood 58:1069–1074, 1981.
667. Reinhardt C, et al: Protein disulfide isomerase acts as an injury response signal that 701. Smariga PE, Maynard JR: Purification of a platelet protein which stimulates fibrino-
enhances fibrin generation via tissue factor activation. J Clin Invest 118(3):1110–1122, lytic inhibition and tissue factor in human fibroblasts. J Biol Chem 257:11960–11965,
2008. 1982.
668. Smith SA, et al: Polyphosphate modulates blood coagulation and fibrinolysis. Proc 702. Jang IK, et al: Differential sensitivity of erythrocyte-rich and platelet-rich arterial
Natl Acad Sci U S A 103(4):903–908, 2006. thrombi to lysis with recombinant tissue-type plasminogen activator. A possible
669. Smith SA, Morrissey JH: Polyphosphate enhances fibrin clot structure. Blood explanation for resistance to coronary thrombolysis. Circulation 79:920–928, 1989.
112(7):2810–2816, 2008. 703. Fitzgerald DJ, et al: Marked platelet activation in vivo after intravenous streptokinase
670. Bouchard BA, et al: Interactions between platelets and the coagulation system, in in patients with acute myocardial infarction. Circulation 77:142–150, 1988.
Platelets, edited by AD Michelson, pp 377–402. Academic Press, San Diego, 2007. 704. Fitzgerald DJ, Wright F, FitzGerald GA: Increased thromboxane biosynthesis during
671. Swords NA, Tracy PB, Mann KG: Intact platelet membranes, not platelet-released coronary thrombolysis: Evidence that platelet activation and thromboxane A2 modu-
microvesicles, support the procoagulant activity of adherent platelets. Arterioscler late the response to tissue-type plasminogen activator in vivo. Circ Res 65:83–94, 1989.
Thromb 13(11):1613–1622, 1993. 705. Kerins DM, et al: Platelet and vascular function during coronary thrombolysis with
672. Zwaal RFA, Comfurius P, Bevers EM: Platelet procoagulant activity and microvesi- tissue-type plasminogen activator. Circulation 80:1718–1725, 1990.
cle formation. Its putative role of hemostasis and thrombosis. Biochim Biophys Acta 706. Ohlstein EH, et al: Tissue-type plasminogen activator and streptokinase induce plate-
1180:1–8, 1992. let hyperaggregability in the rabbit. Thromb Res 46:575–585, 1987.
673. Alberio L, et al: Surface expression and functional characterization of alpha-granule 707. Penny WF, Ware JA: Platelet activation and subsequent inhibition by plasmin and
factor V in human platelets: Effects of ionophore A23187, thrombin, collagen, and recombinant tissue-type plasminogen activator. Blood 79(1):91–98, 1992.
convulxin. Blood 95(5):1694–1702, 2000. 708. Rudd MA, et al: Temporal effects of thrombolytic agents on platelet function in vivo
674. Scandura JM, Ahmad SS, Walsh PN: A binding site expressed on the surface of and their modulation by prostaglandins. Circ Res 67(5):1175–1181, 1990.
activated human platelets is shared by factor X and prothrombin. Biochemistry 709. Shebuski RJ: Principles underlying the use of conjunctive agents with plasminogen
35(27):8890–8902, 1996. activators. Ann N Y Acad Sci 667:382–394, 1992.
675. Byzova TV, Plow EF: Networking in the hemostatic system. Integrin alphaiibbeta3 710. Ervin AL, Peerschke EI: Platelet activation by sustained exposure to low-dose plas-
binds prothrombin and influences its activation. J Biol Chem 272(43):27183–27188, min. Blood Coagul Fibrinolysis 12(6):415–425, 2001.
1997. 711. Ishii-Watabe A, et al: On the mechanism of plasmin-induced platelet aggregation.
676. Baglia FA, Walsh PN: Thrombin-mediated feedback activation of factor XI on the Implications of the dual role of granule ADP. Biochem PharmacolAm Rev Respir Dis
activated platelet surface is preferred over contact activation by factor XIIa or factor 59(11):1345–1355, 2000.
XIa. J Biol Chem 275(27):20514–20519, 2000. 712. Niewiarowski S, Senyi AF, Gillies P: Plasmin-induced platelet aggregation and platelet
677. Oliver JA, et al: Thrombin activates factor XI on activated platelets in the absence of release reaction. J Clin Invest 52:1647–1659, 1973.
factor XII. Arterioscler Thromb Vasc Biol., 19(1):170–177, 1999. 713. Schafer AI, et al: Platelet protein phosphorylation, elevation of cytosolic calcium, and
678. Gailani D, et al: Model for a factor IX activation complex on blood platelets: Dimeric inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin
conformation of factor XIa is essential. Blood 97(10):3117–3122, 2001. Invest 78:73–79, 1986.
679. Walsh PN: Platelets and factor XI bypass the contact system of blood coagulation. 714. Quinton TM, et al: Plasmin-mediated activation of platelets occurs by cleavage of pro-
Thromb Haemost 82:234–242, 1999. tease-activated receptor 4. J Biol Chem 279(18):18434–18439, 2004.
680. Coller BS: Platelets and thrombolytic therapy. N Engl J Med 322:33–42, 1990. 715. Eisenberg PR, Sherman LA, Jaffe AS: Paradoxic elevation of fibrinopeptide A after
681. Coller BS: Augmentation of thrombolysis with antiplatelet drugs. Overview. Coron streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am
Artery Dis 6:911–914, 1995. Coll Cardiol 10:527–529, 1987.
682. Kolev K, Machovich R: Molecular and cellular modulation of fibrinolysis. Thromb 716. Leopold JA, Loscalzo J: Platelet activation by fibrinolytic agents: A potential mech-
Haemost 89(4):610–621, 2003. anism for resistance to thrombolysis and reocclusion after successful thrombolysis.
683. Korbut R, Gryglewski RJ: Platelets in fibrinolytic system. J Physiol Pharmacol Coron Artery Dis 6(12):923–929, 1995.
46(4):409–418, 1995. 717. Owen J, et al: Thrombolytic therapy with tissue plasminogen activator or streptoki-
684. Maron BA, Loscalzo J: The role of platelets in fibrinolysis, in Platelets, edited by AD nase induces transient thrombin activity. Blood 72:616–620, 1988.
Michelson, pp 415–430. Academic Press, San Diego, 2007. 718. Szczeklik A: Thrombin generation in myocardial infarction and hypercholester-
685. Carroll RC, et al: Plasminogen, plasminogen activator and platelets in the regulation olemia: Effects of aspirin. Thromb Haemost 74(1):77–80, 1995.
of clot lysis. J Lab Clin Med 100:986–996, 1982. 719. Weitz JI, et al: Human tissue-type plasminogen activator releases fibrinopeptides A
686. de Haan J, van Oeveren W: Platelets and soluble fibrin promote plasminogen activa- and B from fibrinogen. J Clin Invest 82:1700–1707, 1988.
tion causing downregulation of platelet glycoprotein Ib/IX complexes: Protection by 720. Coller BS: Platelets in cardiovascular thrombosis and thrombolysis, in The Heart and
aprotinin. Thromb Res 92(4):171–179, 1998. Cardiovascular System, edited by HA Fozzard, Jennings RB, Katz AM, Morgan HE,
687. Jeanneau C, Sultan Y: Tissue plasminogen activator in human megakaryocytes and Haber E, pp 219–273. Raven Press, New York, 1991.
platelets: Immunocytochemical localization, immunoblotting and zymographic anal- 721. Coller BS: Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive ther-
ysis. Thromb Haemost 19:529–534, 1988. apy for coronary artery thrombolysis. Coron Artery Dis 3:1016–1029, 1992.
688. Miles LA, et al: Plasminogen interacts with human platelets through two distinct 722. Eccleston D, Topol EJ: Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of
mechanisms. J Clin Invest 77:2001–2009, 1986. thrombolysis. Coron Artery Dis 6(12):947–955, 1995.
689. Miles LA, Plow EF: Binding and activation of plasminogen on the platelet surface. J 723. O’Donnell CJ, Jonas MA, Hennekens CH: Aspirin augmentation of the efficacy of
Biol Chem 260:4303–4311, 1985. thrombolysis. Coron Artery Dis 6(12):936–939, 1995.
690. Park S, et al: Demonstration of single chain urokinase-type plasminogen activator on 724. Topol EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic ther-
human platelet membrane. Blood 73:1421–1425, 1989. apy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa
691. Stricker RB, et al: Activation of plasminogen by tissue plasminogen activator on nor- inhibition: The GUSTO V randomised trial. Lancet 357(9272):1905–1914, 2001.
mal and thrombasthenic platelets: Effects on surface proteins and platelet aggregation. 725. Di Mario C, Dudek D, Piscione F, et al: Immediate angioplasty versus standard ther-
Blood 68:275–280, 1986. apy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase
692. Thorsen S, Brakman P, Astrup T: Influence of platelets on fibrinolysis: A critical Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): An open, prospective,
review, in Hematologic Reviews, edited by JL Ambrole, pp 123–179. Marcel Dekker, randomised, multicentre trial. Lancet 371(9612):559–568, 2008.
New York, 1972. 726. Ellis SG, et al: Facilitated PCI in patients with ST-elevation myocardial infarction. N
693. Binder BR, et al: Plasminogen activator inhibitor 1: Physiological and pathophysio- Engl J Med 358(21):2205–2217, 2008.
logical roles. News Physiol Sci 17:56–61, 2002. 727. Lapchak PA, et al: The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist
694. Cox AD, Devine DV: Factor XIIIa binding to activated platelets is mediated through SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage
activation of glycoprotein IIb-IIIa. Blood 83:1006–1016, 1994. after thromboembolic stroke. Stroke 33(1):147–152, 2002.
695. Erickson LA, Ginsberg MH, Loskutoff DJ: Detection and partial characterization of 728. Zhang L, et al: Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor
an inhibitor of plasminogen activator in human platelets. J Clin Invest 74:1465–1472, increases the therapeutic window for low-dose tissue plasminogen activator adminis-
1984. tration in a rat model of embolic stroke. Circulation 107(22):2837–2843, 2003.
696. Fay WP, et al: Platelets inhibit fibrinolysis in vitro by both plasminogen activator 729. Zhang ZG, et al: Dynamic platelet accumulation at the site of the occluded middle
inhibitor-1 dependent and independent mechanisms. Blood 83:351–356, 1994. cerebral artery and in downstream microvessels is associated with loss of microvascu-
697. Francis CW, Marder VJ: Rapid formation of large molecular weight alpha-polymers in lar integrity after embolic middle cerebral artery occlusion. Brain Res 912(2):181–194,
cross-linked fibrin induced by high factor XIII concentrations: Role of platelet factor 2001.
XIII. J Clin Invest 80:1459–1465, 1987. 730. Adams HP Jr, et al: Emergency administration of abciximab for treatment of patients
698. Kawasaki T, et al: Vascular release of plasminogen activator inhibitor-1 impairs with acute ischemic stroke: Results of an international phase III trial: Abciximab in
fibrinolysis during acute arterial thrombosis in mice. Blood 96(1):153–160, 2000. Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 39(1):87–99, 2008.
699. Kruithof EKO, Tran-Thang C, Bachmann F: Studies on the release of plasminogen 731. Mandava P, Thiagarajan P, Kent TA: Glycoprotein IIb/IIIa antagonists in acute
activator inhibitor from human platelets. Thromb Haemost 55:201–205, 1986. ischaemic stroke: Current status and future directions. Drugs 68(8):1019–1028, 2008.

Kaushansky_chapter 112_p1829-1914.indd 1896 17/09/15 3:30 pm